Brainstorm Cell Therapeutics Inc • BCLI

Capital at risk.

About Brainstorm Cell Therapeutics Inc
Ticker
info
BCLI
Trading on
info
NASDAQ
ISIN
info
US10501E2019
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Chaim Lebovits
Headquarters
info
1325 Avenue of Americas, New York, NY, United States, 10019
Employees
info
29
Website
info
brainstorm-cell.com
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Metrics
BasicAdvanced
Market cap
info
$8.2M
P/E ratio
info
-
EPS
info
-$3.45
Dividend Yield
info
0.00%
Beta
info
0.74
Forward P/E ratio
info
0
EBIDTA
info
$-13.1M
Ex dividend date
info
-
Price & volume
Market cap
info
$8.2M
Average daily volume
info
0M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
65.82
Earnings
EPS
info
-$3.45
EPS estimate (current quarter)
info
-$0.70
EPS estimate (next quarter)
info
-$0.28
EBITDA
info
$-13.1M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.74
52-week High
info
$11.25
52-week Low
info
$1.05
50-day moving average
info
$1.75
200-day moving average
info
$3.07
Short ratio
info
4.54
Short %
info
2.27%
Management effectiveness
ROE (TTM)
info
1,121.90%
ROA (TTM)
info
215.84%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
5.7M
Float
info
4.4M
Insiders %
info
20.84%
Institutions %
info
12.49%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$14.45
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$1.50
-$1.65
9.09%
Q4 • 23Beat
-$0.04
-$0.07
42.86%
Q1 • 24Beat
-$0.04
-$0.04
-
Q2 • 24Beat
-$0.51
-$0.70
27.14%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0.4M
$-2.5M
696.16%
Q2 • 24
$0M
$-2.7M
∞%
Q3 • 24
100.00%
6.57%
∞%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$5.7M
$9.2M
162.06%
Q2 • 24
$2M
$8.1M
399.11%
Q3 • 24
64.37%
12.25%
146.27%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-1.7M
$0M
$4.4M
$-1.7M
Q2 • 24
$-3.3M
$0M
$0M
$-3.3M
Q3 • 24
96.02%
-
100.00%
96.02%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Brainstorm Cell Therapeutics Inc share?
Collapse

Brainstorm Cell Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Brainstorm Cell Therapeutics Inc have?
Collapse

Brainstorm Cell Therapeutics Inc currently has 5.7M shares.

Does Brainstorm Cell Therapeutics Inc pay dividends?
Collapse

No, Brainstorm Cell Therapeutics Inc doesn't pay dividends.

What is Brainstorm Cell Therapeutics Inc 52 week high?
Collapse

Brainstorm Cell Therapeutics Inc 52 week high is $11.25.

What is Brainstorm Cell Therapeutics Inc 52 week low?
Collapse

Brainstorm Cell Therapeutics Inc 52 week low is $1.05.

What is the 200-day moving average of Brainstorm Cell Therapeutics Inc?
Collapse

Brainstorm Cell Therapeutics Inc 200-day moving average is $3.07.

Who is Brainstorm Cell Therapeutics Inc CEO?
Collapse

The CEO of Brainstorm Cell Therapeutics Inc is Chaim Lebovits.

How many employees Brainstorm Cell Therapeutics Inc has?
Collapse

Brainstorm Cell Therapeutics Inc has 29 employees.

What is the market cap of Brainstorm Cell Therapeutics Inc?
Collapse

The market cap of Brainstorm Cell Therapeutics Inc is $8.2M.

What is the P/E of Brainstorm Cell Therapeutics Inc?
Collapse

The current P/E of Brainstorm Cell Therapeutics Inc is null.

What is the EPS of Brainstorm Cell Therapeutics Inc?
Collapse

The EPS of Brainstorm Cell Therapeutics Inc is -$3.45.

What is the PEG Ratio of Brainstorm Cell Therapeutics Inc?
Collapse

The PEG Ratio of Brainstorm Cell Therapeutics Inc is 0.

What do analysts say about Brainstorm Cell Therapeutics Inc?
Collapse

According to the analysts Brainstorm Cell Therapeutics Inc is considered a buy.